Alvogen today announced its collaboration with the Massachusetts Institute of Technology (MIT) through its Industrial Liaison Program (ILP). The program is industry's chief guide and gateway to the vast resources at MIT, a world leader in education and research.
- Connects Alvogen with people, ideas and solutions at MIT
- Stimulates new thinking to support corporate growth
- Provides a great learning and collaboration platform for Alvogen
Parsippany, New Jersey, June 20th, 2011 - Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced its collaboration with the Massachusetts Institute of Technology (MIT) through its Industrial Liaison Program (ILP). The program is industry's chief guide and gateway to the vast resources at MIT, a world leader in education and research. With nearly 200 of the world’s leading companies as its membership, the program provides Alvogen with access to extensive expertise and represents an excellent learning and collaboration platform.
“The pharmaceuticals industry is facing challenges and competition in the area of specialty generics is getting severe. Companies need to find new ways for growth and drive internal innovation by bringing new products to market quickly and being clever in identifying the best products and markets. To complement our strong internal capabilities, Alvogen also relies heavily on collaborations with business partners from around the world. This exciting collaboration is designed to help us create a top ten global player in generics and bring our management close to the many innovative thinkers and developers at MIT,” commented Robert Wessman, Executive Chairman of Alvogen.
Alvogen's Senior Industrial Liaison Officer at MIT, Marie-Teresa Vander Sande, praised the collaboration, saying: "We are excited to be working with Alvogen and are committed to helping this energetic company derive maximum value from its relationship with MIT through the Industrial Liaison Program."
Get more information on Alvogen and MIT: